This article explores effective medical treatments for wet age-related macular degeneration, including anti-angiogenic drugs, photodynamic therapy, and laser procedures. Early intervention and regular treatment are key to managing this condition. The content aims to inform patients about available options and emphasizes consulting healthcare professionals for tailored care.

Wet age-related macular degeneration (AMD) is a chronic eye disorder that can cause partial vision loss and distortions. It occurs when abnormal blood vessels grow under the retina and leak fluid into the macula, impairing sharp vision. While no cure exists, early medical interventions can slow down or stop disease progression. Some patients may even experience improvement in vision with timely treatments.

Medical Treatments

Anti-angiogenic drugs are the primary treatment, designed to inhibit abnormal vessel growth by targeting specific growth factors. These medications include brolucizumab (Beovu®), aflibercept (Eylea®), ranibizumab (Lucentis®), bevacizumab (Avastin®), and pegaptanib sodium (Macugen®), all approved by the FDA. Administered through regular injections into the eye, consistent treatment enhances outcomes.

Photodynamic Therapy (PDT)

This procedure involves injecting a drug into the bloodstream, which accumulates in abnormal vessels. A laser activates the drug, sealing leaky vessels. Each session typically lasts around 20 minutes, with additional sessions possibly needed according to individual cases.

Laser Therapy

In targeted cases, laser photocoagulation can treat leaking vessels by sealing them with a specialized laser after numbing the eye. While it can prevent further deterioration, it may cause scarring and permanent blind spots. Recurrent abnormal vessel growth is a possible concern, especially in severe cases.

Disclaimer: Our blog provides educational health guidance based on current research but is not a substitute for professional medical advice. Users should consult healthcare providers for personalized treatment options.